Jorge Cortes comes to the Georgia Cancer Center after spending the last 23 years at The University of Texas MD Anderson Cancer Center, where he has taken on many roles in the Department of Leukemia, Division of Cancer Medicine; including his roles as the Deputy Department Chair, the Chair of AML and CML Sections, Professor of Medicine and Internist. In addition, Cortes held the title of Jane and John Justin Distinguished Chair in Leukemia Research and was the Leukemia Fellowship Program Director. He was also the Deputy Division Head for the Cancer Network, and Chair of the Executive IRB at MD Anderson.
Cortes obtained his undergraduate and post-graduate training in Mexico City before completing his fellowship in Houston, TX. He has over 230 grants and contracts where he was principal investigator. He has authored nearly 1,000 peer-review original research articles with numerous other accolades towards his name and practice.
The Cortes family, Jorge, his wife and two children, will be transferring to the Augusta area from Houston. They are excited to experience all the beauty and culture our area has to offer and will enjoy the cooler weather.
Areas of Expertise (12)
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Blood and Bone Marrow Transplants
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Leukemia and Lymphoma
John Goldman Prize, International CML Foundation
Samuel J. Hassenbush III, M.D., Ph.D., Physicians Referral Service Leadership and Institutional Service Award (LISA), MDACC,
Institutional Service Award (LISA), MDACC (professional)
2016 Cattlemen for Cancer Research Hero Award (CCR), Cattlemen for Cancer Research
Andrew Sabin Family Fellows, MDACC
Meet Houston's Top Doctors 2016, The Medcity
Facultad de Medicina, Universidad Nacional Autónoma de Mexico,: M.D. 1986
Centro Universitario Mexico: B.S., Biological Sciences 1979
Instituto Nacional de la Nutricion Salvador Zubiran: 1986−1989, Residency in Internal Medicine
Instituto Nacional de la Nutricion Salvador Zubiran: 1989−1990, Medical Chief Resident
Instituto Nacional de la Nutricion Salvador Zubiran: 1990−1992, Hematology Fellowship
The University of Texas MD Anderson Cancer Center: 1992−1995, Hematology/Oncology Fellowship
University of Texas Health Science Center at Houston: 1991−1992, Hematology Fellowship
Media Appearances (5)
Georgia Cancer Center gets new director
The Augusta Chronicle
Dr. Jorge Cortes is excited about the research and the potential at Georgia Cancer Center but what attracted him most was the chance to reach out and improve treatment for minority and underserved populations in Georgia that bear a higher burden from the disease...
Peer-Reviewed Journal Future Oncology Publishes Two Manuscripts on Cancer Metabolism and Drug Candidate CPI-613® (Devimistat)
One paper addresses the evaluation of the efficacy of devimistat in the treatment of pancreatic cancer, authored by Dr. Philip Philip, oncologist and clinical professor of oncology at the Barbara Ann Karmanos Cancer Institute at Wayne State University. The other paper addresses the use of devimistat for the treatment of acute myeloid leukemia (AML), authored by Dr. Jorge Cortes, director of the Georgia Cancer Center at Augusta University...
Georgia Cancer Center receives $6 million grant to improve access to clinical trials
"The awarding of this grant is a recognition of the efforts of Dr. Ghamande and the commitment of the Georgia Cancer Center to improve cancer care in our communities," said Dr. Jorge Cortes, director of the Georgia Cancer Center. "There has been tremendous progress in our fight against cancer. Unfortunately, many patients do not have access to the most advanced therapies and clinical trials. By extending the participation in clinical trials of underserved and minority populations in Georgia and Mississippi through this grant, we can improve their long-term outlook."...
Big grant helps Georgia Cancer Center reach across the state
The Augusta Chronicle
The center is one of 14 National Cancer Institute Community Oncology Research Program (NCORP) Minority/Underserved Community Sites across the country and will use the six-year grant to partner with others in the state and one site in Mississippi to open up access to clinical trials and also look at issues such as prevention or interventions that could help patients avoid cancer, said Dr. Jorge Cortes, the center’s new director...
Cancer center’s new chief starts transition
The Augusta Chronicle
As a pioneering drug developer himself, Dr. Jorge Cortes knows the need to study not only why some patients benefit from a cancer drug but also why some did not and how that fits into the complex environment of treating individual cancers...
Jain P, Kantarjian H, Boddu PC, et al.
Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The incidence and characteristics across different TKI have not been systematically analyzed. We analyzed 531 patients treated with frontline TKIs in different prospective trials: imatinib 400 mg (n = 71) and 800 mg (n = 203), nilotinib (n = 108), dasatinib (n = 106), and ponatinib (n = 43).
Cortes J, Rea D, Lipton JH.
Chronic myeloid leukemia (CML) has become a chronic disease, for which the chronic phase is manageable with tyrosine kinase inhibitor (TKI) therapy. Patients with optimal responses to TKIs have achieved long‐term survival, and treatment‐free remission (TFR) has since become an additional treatment goal in CML. In this review, we discuss important factors to consider prior to stopping treatment. In addition, published and presented data with the first‐generation TKI imatinib, as well as current clinical trials evaluating TFR with the second‐generation TKIs dasatinib and nilotinib, are examined.
Cortes JE, Kim DW, Pinilla-Ibarz J, et al.
Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial evaluated efficacy and safety of ponatinib at a starting dose of 45 mg once daily in 449 patients with chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) resistant/intolerant to dasatinib or nilotinib, or with BCR-ABL1T315I. This analysis focuses on chronic-phase CML (CP-CML) patients (n = 270) with 56.8-month median follow-up.
Cortes JE, Gambacorti-Passerini C, Deininger MW, et al.
Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. We assessed the efficacy and safety of bosutinib versus imatinib for first-line treatment of chronic-phase CML.